Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) gapped up before the market opened on Monday . The stock had previously closed at $12.05, but opened at $12.46. Dyne Therapeutics shares last traded at $12.21, with a volume of 437,345 shares traded.
Analyst Ratings Changes
DYN has been the topic of a number of research analyst reports. Piper Sandler cut their target price on shares of Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating on the stock in a research report on Friday, February 28th. Robert W. Baird started coverage on Dyne Therapeutics in a research note on Friday, December 13th. They issued an "outperform" rating and a $46.00 price target for the company. Baird R W upgraded Dyne Therapeutics to a "strong-buy" rating in a research report on Thursday, December 12th. Chardan Capital reiterated a "buy" rating and issued a $50.00 target price on shares of Dyne Therapeutics in a research report on Monday. Finally, HC Wainwright restated a "buy" rating and set a $46.00 price target on shares of Dyne Therapeutics in a report on Monday. One analyst has rated the stock with a sell rating, one has given a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $47.46.
Read Our Latest Analysis on Dyne Therapeutics
Dyne Therapeutics Stock Performance
The stock has a fifty day simple moving average of $13.68 and a two-hundred day simple moving average of $24.49. The stock has a market capitalization of $1.37 billion, a price-to-earnings ratio of -3.39 and a beta of 1.11.
Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its earnings results on Tuesday, March 4th. The company reported ($0.88) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.04. Research analysts forecast that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.
Insider Activity
In other news, insider Oxana Beskrovnaya sold 2,598 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total transaction of $36,242.10. Following the transaction, the insider now owns 199,087 shares of the company's stock, valued at $2,777,263.65. This represents a 1.29 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold 6,237 shares of company stock worth $77,760 in the last quarter. 20.77% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the company. Quantbot Technologies LP bought a new stake in shares of Dyne Therapeutics during the third quarter valued at approximately $34,000. Point72 DIFC Ltd acquired a new stake in Dyne Therapeutics in the 3rd quarter valued at $36,000. GF Fund Management CO. LTD. acquired a new stake in Dyne Therapeutics in the 4th quarter valued at $50,000. KBC Group NV increased its stake in Dyne Therapeutics by 53.4% during the 3rd quarter. KBC Group NV now owns 2,157 shares of the company's stock valued at $77,000 after purchasing an additional 751 shares in the last quarter. Finally, Quest Partners LLC raised its holdings in Dyne Therapeutics by 898.3% during the third quarter. Quest Partners LLC now owns 3,434 shares of the company's stock worth $123,000 after buying an additional 3,090 shares during the last quarter. 96.68% of the stock is owned by institutional investors and hedge funds.
Dyne Therapeutics Company Profile
(
Get Free Report)
Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
See Also
Before you consider Dyne Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dyne Therapeutics wasn't on the list.
While Dyne Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
